Active tuberculosis in individuals infected with human immunodeficiency virus after isoniazid prophylaxis

被引:23
|
作者
Fitzgerald, DW
Morse, MM
Pape, JW
Johnson, WD
机构
[1] Cornell Univ, Coll Med, Div Int Med & Infect Dis, New York, NY 10021 USA
[2] Grp Haitien Etud Sarcome Kaposi & Infect Opportun, Port Au Prince, Haiti
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
关键词
D O I
10.1086/317485
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A review was conducted in Haiti to determine the timing and outcome of active tuberculosis (TB) in human immunodeficiency virus (HIV)-positive patients who had previously received isoniazid (INH) prophylaxis. Of 1005 HIV-seropositive patients who completed INH prophylaxis, 14 (1.4%) subsequently had active TB diagnosed. The median interval between discontinuation of INH prophylaxis and TB diagnosis was 8 months for 6 patients receiving 6 months of INH, 22 months for 5 patients receiving 12-24 months of INH, and 40 months for 3 patients receiving 24-36 months of INH (P=.026). There is a postprophylaxis effect on INH that is dependent upon the duration of therapy.
引用
收藏
页码:1495 / 1497
页数:3
相关论文
共 50 条
  • [1] Secondary prophylaxis for tuberculosis in patients infected with human immunodeficiency virus
    Shuter, J
    Bellin, E
    CLINICAL INFECTIOUS DISEASES, 1996, 22 (02) : 398 - 399
  • [2] Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients
    Casado, JL
    Moreno, S
    Fortún, J
    Antela, A
    Quereda, C
    Navas, E
    Moreno, A
    Dronda, F
    CLINICAL INFECTIOUS DISEASES, 2002, 34 (03) : 386 - 389
  • [3] Secondary prophylaxis for tuberculosis in patients infected with human immunodeficiency virus - Reply
    Castro, KG
    Blinkhorn, RJ
    Ellner, JJ
    Chaisson, RE
    Horsburgh, CR
    Masur, H
    Holmes, KK
    Kaplan, JE
    CLINICAL INFECTIOUS DISEASES, 1996, 22 (02) : 399 - 400
  • [4] Risk Factors for Developing Active Tuberculosis After the Treatment of Latent Tuberculosis in Adults Infected With Human Immunodeficiency Virus
    Amoakwa, Kojo
    Martinson, Neil A.
    Moulton, Lawrence H.
    Barnes, Grace L.
    Msandiwa, Reginah
    Chaisson, Richard E.
    OPEN FORUM INFECTIOUS DISEASES, 2015, 2 (01):
  • [5] Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients
    Schluger, NW
    CLINICAL INFECTIOUS DISEASES, 1999, 28 (01) : 130 - 135
  • [6] Incidence of tuberculosis in human immunodeficiency virus-infected children in India: Is there a role of isoniazid preventive therapy
    Shetty, Naman S.
    Shah, Ira
    INDIAN JOURNAL OF SEXUALLY TRANSMITTED DISEASES AND AIDS, 2019, 40 (01) : 25 - 29
  • [7] Relapse of tuberculosis after treatment in human immunodeficiency virus-infected patients
    Pulido, F
    Pena, JM
    Rubio, R
    Moreno, S
    Gonzalez, J
    Guijarro, C
    Costa, JR
    Vazquez, JJ
    ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (02) : 227 - 232
  • [8] High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus
    Jarrett, Ryan T.
    van der Heijden, Yuri
    Shotwell, Matthew S.
    Chihota, Violet
    Marzinke, Mark A.
    Chaisson, Richard E.
    Dooley, Kelly E.
    Churchyard, Gavin J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (02)
  • [9] TUBERCULOSIS IN 30 PATIENTS INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS
    PERRONNE, C
    ZAHRAOUI, M
    LEPORT, C
    SALMON, D
    PANGON, B
    BRICAIRE, F
    VILDE, JL
    PRESSE MEDICALE, 1988, 17 (29): : 1479 - 1483
  • [10] TUBERCULOSIS IN PATIENTS INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS
    ONG, ELC
    MANDAL, BK
    QUARTERLY JOURNAL OF MEDICINE, 1991, 80 (291): : 613 - 617